Start with two full samples. Sign in for this edition’s free story. Sources and corrections stay open.
What the pen marks mean
rememberThe takeaway: what to remember
figureThe number that matters
evidenceThe evidence line
rulingThe ruling
claimThe claim that fails
Each mark is drawn once, as you reach it. Numbers are only circled when they come from the story’s own figures.
01 / ScienceTrue, butFree sample
Microsoft's AI really did more than double doctors' accuracy in Science. The doctors were generalists working alone, the patients were simulated, and every author works for Microsoft.
Microsoft AI (MAI Health Team), 22 October 2026, announcing its Science paper; shared on r/artificial as AI doubling doctors' accuracy ·
AI illustration
MAI-DxO scored 83.2% on hard NEJM cases against 36.1% for generalists with references. The authors say it shows nothing against specialists, teams or real clinics. A prospective test is only announced.
The reality check
It scored 83.2% on NEJM case conferences against 36.1% for generalists using references, on 56 held-out cases in a simulator. The authors, all Microsoft employees, say it shows no superiority over specialists, teams or real practice. THE VERDICT: Needs context. A real benchmark win, not a clinical one. THE VERDICT: Needs context.
Why care? For hard diagnostic puzzles, this is strong evidence the tool could help a lone generalist. It says nothing yet about patients in a real hospital, and the real-world study has only been announced.
Take this with youMicrosoft's AI beat solo generalists 83% to 36% on 56 simulated cases; its own authors say that shows nothing against specialists or real clinics.
Open the evidence3 source pages +
The claim we checked
MAI-DxO is more than twice as accurate as physicians using textbooks and the internet
These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.
Through a new partnership with Beth Israel Deaconess Medical Center in Boston, we will evaluate clinical reasoning capabilities across different hospital settings.
The AI cancer 'treatment' is one plant compound that worked alongside an existing drug on cancer cell clumps in a dish. No mice, no patients yet.
Headline trending on r/artificial, October 2026, on UCLA's MAESTRO study in Advanced Science ·
AI illustration
UCLA's MAESTRO ranked 3,592 natural products. 23 of its 150 top picks showed synergy in lab spheroids, and berberine stood out. Animal studies are the next step, not the last.
The reality check
UCLA's MAESTRO ranked 3,592 natural products as add-ons to enzalutamide; 23 of 150 picks showed synergy in 3D prostate cancer spheroids, and berberine stood out. The paper calls it an in vitro hit. Animal studies come next. THE VERDICT: Needs context. A promising lab screen, not a treatment. THE VERDICT: Needs context.
Why care? A tool that narrows thousands of compounds to a testable shortlist is useful to labs. Nobody with prostate cancer can be given this combination on the strength of this study.
Take this with youThe AI picked a promising drug pair, but it was tested only on cancer cell clumps in a dish. No animal or patient results exist, so there is no treatment yet.
Open the evidence3 source pages +
The claim we checked
New AI unlocks a cancer treatment, and scientists are stunned
These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.
Banks found 'rogue' AI agents in customer accounts. Mostly, those are agents customers let in with their own passwords, and nobody published a count.
Axios scoop (via Yahoo Finance), 22 October 2026, citing unnamed sources; amplified on r/artificial ·
AI illustration
Axios says banks detect unauthorized agents and some appear to act on their own. The described case is customer-shared logins, there is no incident count, and the one named bank on record says it has seen none.
Free with your account
Sign in for this free check.
This edition’s selected free story opens after sign-in.
The 42.9% is 36 people. All 84 in the study were screened at Biograph, and every author works for Biograph.
Biograph press release, 22 October 2026, on its medRxiv preprint using Caristo Diagnostics' CaRi-Heart ·
AI illustration
Biograph's preprint used Caristo's FDA-authorised CaRi-Heart on 84 symptom-free adults. It counts flagged arteries, not heart attacks, and the press release smooths over one blood-test result.
Members · 30 days free
See what the evidence actually shows.
Members read the full check on every story: what the evidence shows, why it matters to you and the one line to take with you. Every past edition, re-verified, and the Receipts Pack come with it. A$89 a year, about A$0.24 a day.
At sign-up: 30 days free. Payment card required. One introductory trial per customer.
Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.
A curated directory. Check each entry’s date and sources.
Make a little room for clarity.
Get the next checked edition in your inbox.
At sign-up: 30 days free. Payment card required. One introductory trial per customer.
Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.
